Wilbanks Smith & Thomas Asset Management LLC Fennec Pharmaceuticals Inc. Transaction History

Wilbanks Smith & Thomas Asset Management LLC

$3.54 Billion
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Feb 08, 2019	SELL	$5.37 - $8.39 $537 - $839	-100 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$7.84 - $10.83 $784 - $1,083	100 New	100 $1,000

Others Institutions Holding FENC

# of Institutions

Shares Held

14.3M

Call Options Held

10K

Put Options Held

83.8K

Southpoint Capital Advisors LP New York, NY

4.08M
Shares

$21.6 Million
0.73% of portfolio
Sonic Gp LLC Honolulu, HI

2.41M
Shares

$12.7 Million
30.37% of portfolio
Dg Capital Management, LLC New York, NY

1.63M
Shares

$8.65 Million
3.85% of portfolio
Solas Capital Management, LLC Darien, CT

1.34M
Shares

$7.09 Million
4.92% of portfolio
Black Rock Inc. New York, NY

1.19M
Shares

$6.28 Million
0.0% of portfolio

View Full List

About FENNEC PHARMACEUTICALS INC.

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $138M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

More about FENC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wilbanks Smith & Thomas Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wilbanks Smith & Thomas Asset Management LLC with notifications on news.

Account